Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials

Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials

Lefamulin was the first systemic pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia based on two phase 3 trials (Lefamulin Evaluation Against Pneumonia [LEAP]-1 and LEAP-2). This pooled analysis evaluated lefamulin efficacy and safety...

Full description

Bibliographic Details
Main Authors: Susanne Paukner, David Mariano, Anita F. Das, Gregory J. Moran, Christian Sandrock, Ken B. Waites, Thomas M. File
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Antibiotics
Subjects:
atypical pathogens
lefamulin
community-acquired bacterial pneumonia
<i>Mycoplasma pneumoniae</i>
<i>Chlamydia pneumoniae</i>
<i>Legionella pneumophila</i>
Online Access:https://www.mdpi.com/2079-6382/10/12/1489

Similar Items

Similar Items